Adalimumab VS. Conventional immunosuppression for uveitis(advise) trial

Ended Cooperative Agreement Awarded Last action

Award ID
UG1EY028091
Recipient
Awarding agency
Obligated
$16,207,663

Award facts

Assistance listing
93.867 Vision Research
Completion date
Originally
Funding
  • $13,566,842.29 Federal
  • $2,640,821.00 Non-federal
Place of performance
Maryland, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment -$23,111 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $972,337 $0
Amendment $972,337 $0
Amendment $972,337 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $2,640,821 $0
Amendment $2,640,821 $2,640,821
Amendment $93,172 $0
Amendment $2,623,848 $0
Amendment $1,915,534 $0
Original award $758,746 $0
Show all 19

Subawards

Subrecipient Amount Awarded
Subrecipient not on record The ADVISE Trial is a randomized comparative effectiveness trial comparing adalimumab to conventional agent immunosuppression for corticosteroid sparing in… $353,295
Retina Consultants Of Houston, PLLC ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial $296,760
University Of Miami The study protocol will require clinic personnel to screen for eligible subjects; obtain subject consent; administer study treatments; collect data on… $244,638
Emory University $147,645
The University Of Iowa ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial $130,953
Subrecipient not on record The study protocol will require clinic personnel to screen for eligible subjects; obtain subject consent; administer study treatments; collect data on… $248,170
Vanderbilt University Medical Center ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial $134,140
Northwestern University The study protocol will require clinic personnel to screen for eligible subjects; obtain subject consent; administer study treatments; collect data on… $74,210
Royal Victorian Eye & Ear Hospital ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial $254,460
University Of California, LOS Angeles The study protocol will require clinic personnel to screen for eligible subjects; obtain subject consent; administer study treatments; collect data on… $172,220
The Washington University ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial $111,528
Subrecipient not on record $280,660
University Of Sydney The ADVISE Coordinating Center (CC) at Johns Hopkins University will establish a subagreement with The University of Sydney will be responsible for conducting… $43,160
The Regents Of The University Of California. San Francisco The study protocol will require clinic personnel to screen for eligible subjects; obtain subject consent; administer study treatments; collect data on… $169,417
Subrecipient not on record ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial $557,347
Regents Of The University Of Michigan ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial. $113,570
The Trustees Of The University Of Pennsylvania $54,010
The Research Institute Of The Mcgill University Health Centre "Adalimumab Vs. conevetional ImmunoSuppresion for uveitis (ADVISE) Trial." $77,625
University Of Pittsburgh - Of The Commonwealth System Of Higher Education ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial $63,808
University Of Washington The study protocol will require clinic personnel to screen for eligible subjects; obtain subject consent; administer study treatments; collect data on… $64,708
Subrecipient not on record The study protocol will require clinic personnel to screen for eligible subjects; obtain subject consent; administer study treatments; collect data on… $139,830
University Of Utah $172,935
Rush University Medical Center ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial $119,830
Subrecipient not on record $133,750
The Research Institute Of The Mcgill University Health Centre ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial. $67,625
Show all 25

Quick answers

Who received award UG1EY028091?

UG1EY028091 was awarded to The Johns Hopkins University by National Eye Institute (National Institutes of Health) on September 30, 2018.

How much is award UG1EY028091 worth?

$16,207,663 has been obligated on UG1EY028091: $13,566,842 in federal funding and $2,640,821 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login